Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

Fudan University

Status: Completed

Conditions: Metastatic Breast Cancer

Treatments: Drug: Palbociclib

Study type: Observational

Funder types: Other

Identifiers

NCT04992156

YOUNGBC-15

Details and patient eligibility

About

To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.

Enrollment: 50 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Female patients aged 18-70 years.
2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
3. HR+ was defined as estrogen receptor- or progesterone receptor-positive status by immunohistochemistry.
4. HER2 status was determined by immunohistochemistry or fluorescence in situ hybridization.
5. Palbociclib treatment of metastatic breast cancer for at least one cycle.
6. Available medical history.

Exclusion criteria

1.Incomplete medical history.

Trial design

50 participants in 1 patient group

Patients cohort

Description:

Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FES PET/CT before the initiation of Palbociclib was included.

Treatment:

Drug: Palbociclib